Ovid Therapeutics Inc. Cash and Restricted Cash
Ovid Therapeutics Inc. (OVID) had Cash and Restricted Cash of $13.26 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13.26M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $96.00M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.08M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $22.54M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $13.26M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $96.00M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $15.08M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $22.54M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $30.35M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $23.07M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $28.23M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $16.95M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $31.63M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $32.70M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $28.97M 10-K · filed 2026-03-18 | $28.97M 10-K · filed 2024-03-08 |
| 2023-09-30 | $59.37M 10-Q · filed 2024-11-12 | $59.37M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $73.55M 10-Q · filed 2024-08-13 | $73.55M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $64.98M 10-Q · filed 2024-05-14 | $64.98M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $46.80M 10-K · filed 2025-03-11 | $46.80M 10-K · filed 2023-03-13 |
| 2022-09-30 | $60.19M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $74.74M 10-Q · filed 2023-08-04 | |
| 2022-03-31 | $168.60M 10-Q · filed 2023-05-05 | |
| 2021-12-31 | $189.73M 10-K · filed 2024-03-08 | |
| 2021-09-30 | $201.78M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $212.17M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $233.05M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $72.03M 10-K · filed 2023-03-13 | |
| 2020-09-30 | $86.87M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $41.25M 10-Q · filed 2021-08-16 | |
| 2020-03-31 | $27.34M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $41.90M 10-K · filed 2022-03-15 | |
| 2019-09-30 | $37.91M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $47.36M 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $54.60M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $36.49M 10-K · filed 2021-03-15 | |
| 2018-09-30 | $30.51M 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $87.13M 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |